BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30015396)

  • 1. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.
    Morgenstern DA; Pötschger U; Moreno L; Papadakis V; Owens C; Ash S; Pasqualini C; Luksch R; Garaventa A; Canete A; Elliot M; Wieczorek A; Laureys G; Kogner P; Malis J; Ruud E; Beck-Popovic M; Schleiermacher G; Valteau-Couanet D; Ladenstein R
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27363. PubMed ID: 30015396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project.
    Moreno L; Guo D; Irwin MS; Berthold F; Hogarty M; Kamijo T; Morgenstern D; Pasqualini C; Ash S; Potschger U; Ladenstein R; Valteau-Couanet D; Cohn SL; Pearson ADJ; London WB
    Pediatr Blood Cancer; 2021 Mar; 68(3):e28794. PubMed ID: 33205902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
    Moroz V; Machin D; Hero B; Ladenstein R; Berthold F; Kao P; Obeng Y; Pearson ADJ; Cohn SL; London WB
    Pediatr Blood Cancer; 2020 Aug; 67(8):e28359. PubMed ID: 32472746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis.
    Corrias MV; Parodi S; Tchirkov A; Lammens T; Vicha A; Pasqualini C; Träger C; Yáñez Y; Dallorso S; Varesio L; Luksch R; Laureys G; Valteau-Couanet D; Canete A; Pöetschger U; Ladenstein R; Burchill SA
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27052. PubMed ID: 29603574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
    Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
    Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
    Yanik GA; Parisi MT; Naranjo A; Nadel H; Gelfand MJ; Park JR; Ladenstein RL; Poetschger U; Boubaker A; Valteau-Couanet D; Lambert B; Castellani MR; Bar-Sever Z; Oudoux A; Kaminska A; Kreissman SG; Shulkin BL; Matthay KK
    J Nucl Med; 2018 Mar; 59(3):502-508. PubMed ID: 28887399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable
    Ambros IM; Tonini GP; Pötschger U; Gross N; Mosseri V; Beiske K; Berbegall AP; Bénard J; Bown N; Caron H; Combaret V; Couturier J; Defferrari R; Delattre O; Jeison M; Kogner P; Lunec J; Marques B; Martinsson T; Mazzocco K; Noguera R; Schleiermacher G; Valent A; Van Roy N; Villamon E; Janousek D; Pribill I; Glogova E; Attiyeh EF; Hogarty MD; Monclair TF; Holmes K; Valteau-Couanet D; Castel V; Tweddle DA; Park JR; Cohn S; Ladenstein R; Beck-Popovic M; De Bernardi B; Michon J; Pearson ADJ; Ambros PF
    J Clin Oncol; 2020 Nov; 38(31):3685-3697. PubMed ID: 32903140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?
    Di Cataldo A; Agodi A; Balaguer J; Garaventa A; Barchitta M; Segura V; Bianchi M; Castel V; Castellano A; Cesaro S; Couselo JM; Cruz O; D'Angelo P; De Bernardi B; Donat J; de Andoin NG; Hernandez MI; La Spina M; Lillo M; Lopez-Almaraz R; Luksch R; Mastrangelo S; Mateos E; Molina J; Moscheo C; Mura R; Porta F; Russo G; Tondo A; Torrent M; Vetrella S; Villegas JA; Viscardi E; Zanazzo GA; Cañete A
    Clin Transl Oncol; 2017 Jan; 19(1):76-83. PubMed ID: 27041689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial.
    Moreno L; Vaidya SJ; Schrey D; Pinkerton CR; Lewis IJ; Kearns PR; Machin D; Pearson ADJ;
    Pediatr Blood Cancer; 2019 Apr; 66(4):e27565. PubMed ID: 30516328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.
    Ladenstein R; Lambert B; Pötschger U; Castellani MR; Lewington V; Bar-Sever Z; Oudoux A; Śliwińska A; Taborska K; Biassoni L; Yanik GA; Naranjo A; Parisi MT; Shulkin BL; Nadel H; Gelfand MJ; Matthay KK; Park JR; Kreissman SG; Valteau-Couanet D; Boubaker A
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):292-305. PubMed ID: 28940046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].
    Fan HJ; Huang C; Su Y; Wang XD; Zhou YC; Duan C; Zhao W; Zhao Q; Jin M; Ma XL
    Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):863-869. PubMed ID: 31665841
    [No Abstract]   [Full Text] [Related]  

  • 12. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.
    Viprey VF; Gregory WM; Corrias MV; Tchirkov A; Swerts K; Vicha A; Dallorso S; Brock P; Luksch R; Valteau-Couanet D; Papadakis V; Laureys G; Pearson AD; Ladenstein R; Burchill SA
    J Clin Oncol; 2014 Apr; 32(10):1074-83. PubMed ID: 24590653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study.
    Holmes K; Pötschger U; Pearson ADJ; Sarnacki S; Cecchetto G; Gomez-Chacon J; Squire R; Freud E; Bysiek A; Matthyssens LE; Metzelder M; Monclair T; Stenman J; Rygl M; Rasmussen L; Joseph JM; Irtan S; Avanzini S; Godzinski J; Björnland K; Elliott M; Luksch R; Castel V; Ash S; Balwierz W; Laureys G; Ruud E; Papadakis V; Malis J; Owens C; Schroeder H; Beck-Popovic M; Trahair T; Forjaz de Lacerda A; Ambros PF; Gaze MN; McHugh K; Valteau-Couanet D; Ladenstein RL;
    J Clin Oncol; 2020 Sep; 38(25):2902-2915. PubMed ID: 32639845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.
    Vo KT; Matthay KK; Neuhaus J; London WB; Hero B; Ambros PF; Nakagawara A; Miniati D; Wheeler K; Pearson AD; Cohn SL; DuBois SG
    J Clin Oncol; 2014 Oct; 32(28):3169-76. PubMed ID: 25154816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
    Schmidt ML; Lukens JN; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Perez C; Haase GM; Matthay KK
    J Clin Oncol; 2000 Mar; 18(6):1260-8. PubMed ID: 10715296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
    Campbell K; Shyr D; Bagatell R; Fischer M; Nakagawara A; Nieto AC; Brodeur GM; Matthay KK; London WB; DuBois SG
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27819. PubMed ID: 31115156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and Prognostic Impact of
    Bellini A; Pötschger U; Bernard V; Lapouble E; Baulande S; Ambros PF; Auger N; Beiske K; Bernkopf M; Betts DR; Bhalshankar J; Bown N; de Preter K; Clément N; Combaret V; Font de Mora J; George SL; Jiménez I; Jeison M; Marques B; Martinsson T; Mazzocco K; Morini M; Mühlethaler-Mottet A; Noguera R; Pierron G; Rossing M; Taschner-Mandl S; Van Roy N; Vicha A; Chesler L; Balwierz W; Castel V; Elliott M; Kogner P; Laureys G; Luksch R; Malis J; Popovic-Beck M; Ash S; Delattre O; Valteau-Couanet D; Tweddle DA; Ladenstein R; Schleiermacher G
    J Clin Oncol; 2021 Oct; 39(30):3377-3390. PubMed ID: 34115544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
    Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
    Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
    Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
    Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
    [No Abstract]   [Full Text] [Related]  

  • 20. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
    Simon T; Spitz R; Faldum A; Hero B; Berthold F
    J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.